Sign in

    Sarah Schram

    Senior Equity Analyst at William Blair

    Sarah Schram is a Senior Equity Analyst at William Blair, specializing in healthcare and biotechnology equity research, with coverage of companies such as Denali Therapeutics, Vigil Neuroscience, Biohaven Ltd., and Xenon Pharmaceuticals. She has issued several outperform ratings, and her coverage history includes a 33.3% success rate and an average return of -3.7% according to TipRanks, with past ratings achieving up to 14.96% average returns on specific calls. Schram began her career in equity research and joined William Blair prior to 2024, with her analyst coverage first recorded in late 2024 and early 2025. She holds professional credentials typical for regulated analysts, such as FINRA registration and securities licenses, and has contributed notable research on innovative pipeline therapeutics.

    Sarah Schram's questions to Xenon Pharmaceuticals (XENE) leadership

    Sarah Schram's questions to Xenon Pharmaceuticals (XENE) leadership • Q4 2024

    Question

    Sarah Schram from William Blair asked if Azetukalner could show benefits on mania in the bipolar depression study and questioned the development strategy for the preclinical Nav1.1 program, including its potential beyond Dravet syndrome.

    Answer

    CMO Dr. Chris Kenney explained that a study in bipolar depression enrolls non-manic patients, so it is not designed to measure or show a benefit in mania. CEO Ian Mortimer addressed the Nav1.1 program, stating the initial focus is Dravet syndrome due to the direct genetic link. He highlighted compelling preclinical data suggesting disease-modifying potential and noted that while the initial focus is Dravet, the mechanism could have broader utility in other epilepsies.

    Ask Fintool Equity Research AI

    Sarah Schram's questions to Xenon Pharmaceuticals (XENE) leadership • Q3 2024

    Question

    Sarah Schram asked whether Xenon plans to pursue both acute and chronic pain indications for its Nav1.7 inhibitor and if the company would ever consider developing a Nav1.8 inhibitor.

    Answer

    CEO Ian Mortimer responded that the Nav1.7 target is applicable to both acute and chronic pain, so while the initial proof-of-concept study will be in acute pain (bunionectomy), all later-stage indications remain possibilities. He confirmed Xenon is focused on Nav1.7 due to stronger genetic validation and its leadership position, and does not have a formal Nav1.8 program.

    Ask Fintool Equity Research AI

    Sarah Schram's questions to Alector (ALEC) leadership

    Sarah Schram's questions to Alector (ALEC) leadership • Q4 2024

    Question

    Inquired about the specifics of the ADP037 preclinical candidate, asking how its pyroglutamate Aβ target epitope differs from competitors like trontinemab, how this could lead to differentiation, and which receptor (TFR or CD98) its brain shuttle system utilizes.

    Answer

    ADP037 targets the PyrGlu3 Aβ epitope, similar to donanemab, which differs from trontinemab's N-terminal target. The company believes differentiation comes from using this validated epitope combined with a fully active Fc and an optimized TFR-mediated shuttle system. The affinity for the TFR receptor has been fine-tuned to optimize brain penetration, half-life, and safety.

    Ask Fintool Equity Research AI